Delivering Glucose Technology to the Masses

Glucovation envisions the delivery of a glucose monitoring solution that is accessible by all that suffer from the various levels of diabetes. Its team of scientists have spent years developing new technology that improves on what is currently available and creating a product set that can be manufactured with the highest quality and the lowest possible cost to the consumer. Glucovation believes that everyone has the right to have technology reach them regardless of where they are in the world.



Glucovation’s CGM sensor detects glucose electrochemically via a proprietary non-enzymatic sensing technology. The sensor is painlessly inserted transcutaneously via a simplified “place and go” applicator and measures glucose in the interstitial fluid; the signal will be converted and then transmitted wirelessly to an existing commercial display device (phone, pad, or watch). Glucovation is focused on developing a system that requires no calibration yet is highly accurate for use in the medical and consumer markets. Glucovation is considering several strategic relationships with international manufacturing, development and distribution partners that are best of class. We will use these relationships to scale very quickly and deliver a solution that is unmatched in the market. With the nearly epidemic growth in diabetes, we are committed to delivering a solution that is easy to use, highest quality, best accuracy, and at a cost structure that will be very disruptive to the market.

Executive Team

Robert Boock, Ph.D.
Robert Boock, Ph.D.CEO/CTO
of Glucovation
Dr. Boock previously served as the Senior Technical Director of Research and Development at Dexcom where he was responsible for managing the research and development of Dexcom’s CGM membrane and biotechnologies. Full Bio

Jeff Suri, Ph.D.
Jeff Suri, Ph.D.Vice President of Sensor Technologies
and Co-Founder
Dr. Suri has over 13 years of experience developing and testing continuous glucose monitoring technologies and platforms. At Dexcom he served as a Senior Scientist where he led the hands-on development of Dexcom’s future generation sensor technology. Full Bio
Kenneth San Vicente
Kenneth San VicenteVice President of Research and Development,
Electronics and Software and Co-Founder
Kenneth previously served as a Principal Engineer at Dexcom. Most recently he was the systems architect and project lead for their latest generation transmitter/receiver system. He led a team responsible for building the sensor interface… Full Bio

Fernando Corona
Fernando CoronaExecutive Vice President of
Business Development, Marketing and Operations
Fernando Corona brings over 30 years of experience in the IT and Wireless industry with Fortune 500 and startup companies to Glucovation. Fernando has held CEO and senior management positions at Cricket Wireless… Full Bio

Board of Directors

John Burd, Ph.D.
John Burd, Ph.D.Dr. Burd is a co-founder and
General Partner of Sabur Technology
Previously Dr. Burd was Founder & CEO of Oculir, developing a remarkable new non-invasive glucose testing technology. Prior to Oculir, Dr. Burd was a General Partner of Windamere Venture Partners and Chairman & CEO of MiraMedica… Full Bio

Clint McClellan
Clint McClellanFounder and President,
Indie Health
Leveraging 15+ years as a wireless health executive, Clint’s latest venture, Indie Health, is developing a portfolio of the most highly standardized, highly certified and easiest to integrate health devices in the industry. Full Bio

The information provided on this website contain statements related to our future business and future events or developments involving our research and development that may constitute forward-looking statements. These statements may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning.  We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases.  In addition, our representatives may from time to time make oral forward-looking statements.  Such statements are based on the current expectations and certain assumptions of Glucovation’s’ management, of which many are beyond Glucovation’s control.  These are subject to a number of risks, uncertainties and factors.  Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Glucovation may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement.  Glucovation neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.